News of Note—Meissa’s chairman from J&J, Takeda and more

non
In this week's news of note, Meissa named a former Johnson & Johnson executive as chairman. (Pixabay)

Here's some other vaccine news of note for the week.

> Meissa Vaccines named Lawrence Blatt, Ph.D., Johnson & Johnson’s recent global head of infectious diseases and vaccines, as its chairman. Release

Takeda established a Center of Excellence in Singapore for vaccine development. It will hire and train local talent to work on the company's current and future vaccine candidates. Asian Scientist article

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> An American expert told the Philippine Senate that he warned Sanofi on the health risks of Dengvaxia in 2016. The Manila Times article

PharmaJet is close to completing a $5 million financing round to fund the production of 5 million syringes to deliver the polio vaccine. MedCity News article

Valneva started a phase 1 study on its live-attenuated, single-dose vaccine candidate against Chikungunya. Release

> Researchers from Cardiff University have created the world’s first synthetic flu vaccine, which is given orally and is stable at room temperature. Cardiff University article

Suggested Articles

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.